Arvin Halim

Arvin Halim

Auto-generated profile, based on publicly available information

Arvin Halim

Indiana University School of Medicine, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2017 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
PPPaul Pang
Paul Pang
MAMolly Abbott
Molly Abbott
MAMalyun Abdi
Malyun Abdi
QFQuynh-Anh Fucci
Quynh-Anh Fucci
NCNikita Chauhan
Nikita Chauhan
ASAndrew M Siedlecki
Andrew M Siedlecki
Chronic kidney disease (CKD) patients have deficient levels of glutathione peroxidase-3 (GPx3). We hypothesized that GPx3 deficiency may lead to cardiovascular disease in the presence of chronic kidney disease due to an accumulation of reactive oxygen species and decreased microvascular perfusion of the myocardium. To isolate the exclusive effect of GPx3 deficiency in kidney disease–induced cardiac disease, we studied the GPx3 knockout mouse strain (GPx3−/−) in the setting of surgery-induced CKD. Ribonucleic acid (RNA) microarray screening of non-stimulated GPx3−/− heart tissue show increased expression of genes associated with cardiomyopathy including myh7, plac9, serpine1 and cd74 compared with wild-type (WT) controls. GPx3−/− mice underwent surgically induced renal mass reduction to generate a model of CKD. GPx3−/− + CKD mice underwent echocardiography 4 weeks after injury. Fractional shortening (FS) was decreased to 32.9 ± 5.8% in GPx3−/− + CKD compared to 62.0% ± 10.3 in WT + CKD (P < 0.001). Platelet aggregates were increased in the myocardium of GPx3−/− + CKD. Asymmetric dimethylarginine (ADMA) levels were increased in both GPx3−/− + CKD and WT+ CKD. ADMA stimulated spontaneous platelet aggregation more quickly in washed platelets from GPx3−/−. In vitro platelet aggregation was enhanced in samples from GPx3−/− + CKD. Platelet aggregation in GPx3−/− + CKD samples was mitigated after in vivo administration of ebselen, a glutathione peroxidase mimetic. FS improved in GPx3−/− + CKD mice after ebselen treatment. These results suggest GPx3 deficiency is a substantive contributing factor to the development of kidney disease–induced cardiac disease.

Verified
Journal Article
Open access
PDF file
KLKenneth Lim
Kenneth Lim
AHArvin Halim
Arvin Halim
TLTzong-Shi Lu
Tzong-Shi Lu
AAAlan Ashworth
Alan Ashworth
ICIrene Chong
Irene Chong
Accelerated vascular aging is a condition that occurs as a complication of several highly prevalent inflammatory conditions such as chronic kidney disease, cancer, HIV infection and diabetes. Age-associated vascular alterations underlie a continuum of expression toward clinically overt cardiovascular disease. This has contributed to the striking epidemiologic transition whereby such noncommunicable diseases have taken center stage as modern-day global epidemics and public health problems. The identification of α-Klotho, a remarkable protein that confers powerful anti-aging properties has stimulated significant interest. In fact, emerging data have provided fundamental rationale for Klotho-based therapeutic intervention for vascular diseases and multiple other potential indications. However, the application of such discoveries in Klotho research remains fragmented due to significant gaps in our molecular understanding of Klotho biology, as well as hurdles in clinical research and experimental barriers that must first be overcome. These advances will be critical to establish the scientific platform from which future Klotho-based interventional trials and therapeutic enterprises can be successfully launched.

31 October 2022 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
AKAshley Kidwell
Ashley Kidwell
SYShiv Pratap Singh Yadav
Shiv Pratap Singh Yadav
BMBernhard Maier
Bernhard Maier
AZAmy Zollman
Amy Zollman
KNKevin Ni
Kevin Ni
THTakashi Hato
Takashi Hato
Significance Statement: Extreme stress, such as life-threatening sepsis, triggers the integrated stress response and causes translation shutdown, a hallmark of late-phase, sepsis-induced kidney injury. Although a brief period of translation shutdown could be cytoprotective, prolonged translation repression can have negative consequences and has been shown to contribute to sepsis-induced kidney failure. Using a murine model of endotoxemia, the authors show that the duration of stress-induced translation shutdown in the kidney can be shortened by overexpressing protein phosphatase 1 regulatory subunit 15A (Ppp1r15a, also known as GADD34), a key regulator of the translation initiation complex. They achieved overexpression of Ppp1r15a with genetic and oligonucleotide approaches, targeting its upstream open reading frame (uORF). Altering Ppp1r15a expression through its uORF to counter translation shutdown offers a potential strategy for the treatment of sepsis-induced kidney failure. Background: Translation shutdown is a hallmark of late-phase, sepsis-induced kidney injury. Methods for controlling protein synthesis in the kidney are limited. Reversing translation shutdown requires dephosphorylation of the eukaryotic initiation factor 2 (eIF2) subunit eIF2α; this is mediated by a key regulatory molecule, protein phosphatase 1 regulatory subunit 15A (Ppp1r15a), also known as GADD34. Methods: To study protein synthesis in the kidney in a murine endotoxemia model and investigate the feasibility of translation control in vivo by boosting the protein expression of Ppp1r15a, we combined multiple tools, including ribosome profiling (Ribo-seq), proteomics, polyribosome profiling, and antisense oligonucleotides, and a newly generated Ppp1r15a knock-in mouse model and multiple mutant cell lines. Results: We report that translation shutdown in established sepsis-induced kidney injury is brought about by excessive eIF2α phosphorylation and sustained by blunted expression of the counter-regulatory phosphatase Ppp1r15a. We determined the blunted Ppp1r15a expression persists because of the presence of an upstream open reading frame (uORF). Overcoming this barrier with genetic and antisense oligonucleotide approaches enabled the overexpression of Ppp1r15a, which salvaged translation and improved kidney function in an endotoxemia model. Loss of this uORF also had broad effects on the composition and phosphorylation status of the immunopeptidome—peptides associated with the MHC—that extended beyond the eIF2α axis. Conclusions: We found Ppp1r15a is translationally repressed during late-phase sepsis because of the existence of an uORF, which is a prime therapeutic candidate for this strategic rescue of translation in late-phase sepsis. The ability to accurately control translation dynamics during sepsis may offer new paths for the development of therapies at codon-level precision.

1 January 2017 in Kidney International
Verified
Journal Article
Closed access
PPPaul Pang
Paul Pang
MAMolly Abbott
Molly Abbott
SCSteven L. Chang
Steven L. Chang
MAMalyun Abdi
Malyun Abdi
NCNikita Chauhan
Nikita Chauhan
ASAndrew M. Siedlecki
Andrew M. Siedlecki

1 March 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
AHArvin Halim
Arvin Halim
GNGayatri Narayanan
Gayatri Narayanan
THTakashi Hato
Takashi Hato
LHLilun Ho
Lilun Ho
DWDouglas Wan
Douglas Wan
KLKenneth Lim
Kenneth Lim
Background: The myocardial cytoskeleton functions as the fundamental framework critical for organelle function, bioenergetics and myocardial remodeling. To date, impairment of the myocardial cytoskeleton occurring in the failing heart in patients with advanced chronic kidney disease has been largely undescribed. Methods and Results: We conducted a 3‐arm cross‐sectional cohort study of explanted human heart tissues from patients who are dependent on hemodialysis (n=19), hypertension (n=10) with preserved renal function, and healthy controls (n=21). Left ventricular tissues were subjected to pathologic examination and next‐generation RNA sequencing. Mechanistic and interference RNA studies utilizing in vitro human cardiac fibroblast models were performed. Left ventricular tissues from patients undergoing hemodialysis exhibited increased myocardial wall thickness and significantly greater fibrosis compared with hypertension patients ( P <0.05) and control ( P <0.01). Transcriptomic analysis revealed that the focal adhesion pathway was significantly enriched in hearts from patients undergoing hemodialysis. Hearts from patients undergoing hemodialysis exhibited dysregulated components of the focal adhesion pathway including reduced β‐actin ( P <0.01), β‐tubulin ( P <0.01), vimentin ( P <0.05), and increased expression of vinculin ( P <0.05) compared with controls. Cytoskeletal adaptations in hearts from the hemodialysis group were associated with impaired mitochondrial bioenergetics, including dysregulated mitochondrial dynamics and fusion, and loss of cell survival pathways. Mechanistic studies revealed that cytoskeletal changes can be driven by uremic and metabolic abnormalities of chronic kidney disease, in vitro. Furthermore, focal adhesion kinase silencing via interference RNA suppressed major cytoskeletal proteins synergistically with mineral stressors found in chronic kidney disease in vitro. Conclusions: Myocardial failure in advanced chronic kidney disease is characterized by impairment of the cytoskeleton involving disruption of the focal adhesion pathway, mitochondrial failure, and loss of cell survival pathways.

5 July 2022 in Kidney360
Verified
Journal Article
Closed access
PDF file
AHArvin Halim
Arvin Halim
HBHeather N. Burney
Heather N. Burney
XLXiaochun Li
Xiaochun Li
YLYang Li
Yang Li
CTClaudia Tomkins
Claudia Tomkins
KLKenneth Lim
Kenneth Lim
Key Points: The highest fibroblast growth factor 23 (FGF23) quartile had impaired VO2Max and ventilatory exercise response patterns compared with the lowest FGF23 quartile. FGF23 was associated with changes in VO2Max in advanced CKD and after restitution of the failing kidney by transplantation. FGF23 was only associated with the progression of left ventricular mass index in patients with advanced CKD, however this association was lost after adjustment for dialysis status in the final model and was not associated after kidney transplantation in all models. Background: Fibroblast growth factor 23 (FGF23) is a bone-derived phosphatonin that is elevated in chronic kidney disease (CKD) and has been implicated in the development of cardiovascular disease. It is unknown whether elevated FGF23 in CKD is associated with impaired cardiovascular functional capacity, as assessed by maximum exercise oxygen consumption (VO2Max). We sought to determine whether FGF23 is associated with cardiovascular functional capacity in patients with advanced CKD and after improvement of VO2Max by kidney transplantation. Methods: We performed secondary analysis of 235 patients from the Cardiopulmonary Exercise Testing in Renal Failure and After Kidney Transplantation (CAPER) cohort, which recruited patients with stage 5 CKD who underwent kidney transplantation or were waitlisted and hypertensive controls. All patients underwent cardiopulmonary exercise testing (CPET) and echocardiography and were followed longitudinally for 1 year after study enrollment. Results: Patients across FGF23 quartiles differed in BMI (P=0.004) and mean arterial pressure (P<0.001) but did not significantly differ in sex (P=0.5) or age (P=0.08) compared with patients with lower levels of FGF23. Patients with higher FGF23 levels had impaired VO2Max (Q1: 24.2±4.8 ml/min per kilogram; Q4: 18.6±5.2 ml/min per kilogram; P<0.001), greater left ventricular mass index (LVMI; P<0.001), reduced HR at peak exercise (P<0.001), and maximal workload (P<0.001). Kidney transplantation conferred a significant decline in FGF23 at 2 months (P<0.001) before improvement in VO2Max at 1 year (P=0.008). Multivariable regression modeling revealed that changes in FGF23 was significantly associated with VO2Max in advanced CKD (P<0.001) and after improvement after kidney transplantation (P=0.006). FGF23 was associated with LVMI before kidney transplantation (P=0.003), however this association was lost after adjustment for dialysis status (P=0.4). FGF23 was not associated with LVMI after kidney transplantation in all models. Conclusions: FGF23 levels are associated with alterations in cardiovascular functional capacity in advanced CKD and after kidney transplantation. FGF23 is only associated with structural cardiac adaptations in advanced CKD but this was modified by dialysis status, and was not associated after kidney transplantation.